Cyto-Cellect® Human IgG Kappa and Viability Assay Kit: Insights from Romina Durigon

Enhancing Cell Line Development in Cyto-Mine^® Chroma

Discover how the Cyto-Cellect^® Human IgG Kappa and Viability Assay Kit enhances therapeutic cell line development by enabling real-time, multiplexed detection of viable IgG-secreting cells in Cyto-Mine^® Chroma.

Author: Romina Durigon
Senior Field Application Scientist, Sphere Bio

Keywords:  Cell line development, antibody discovery

The Cyto-Cellect® Human IgG Kappa and Viability Assay Kit is a newly launched, innovative solution designed specifically for use with the Cyto-Mine® Chroma Single Cell Analysis Platform. This cutting-edge assay enables simultaneous real-time detection of human IgG-secreting cells and the identification of apoptotic and necrotic cells across all stages—from early apoptosis to late apoptosis and necrosis. 

At the core of the kit are Cyto-Cellect® human IgGk FRET probes, which have been validated for specific binding to CHO cell-secreted human IgGk, and a customised viability dye that selectively targets apoptotic and necrotic cell membranes (Figure 1). 

Figure 1: Schematic of the Cyto-Cellect® human IgG kappa and Viability Assay Kit in action. Each picodroplet encapsulates a single cell, a viability probe consisting of Annexin V conjugated to a far-red fluorophore (red particles) and a pair of IgG-specific fluorescent probes. In the presence of an apoptotic or necrotic cell, Annexin V binds to PS residues exposed on the extracellular side of the cell membrane, leading to an increase in the far-red signal (left). In the presence of a live cell and an IgG-secreting cell, the donor and Acceptor FRET probes bind to human IgGs, forming a ternary FRET complex and triggering fluorescence changes in the green and orange channels (right).